{"id":823452,"date":"2025-03-10T07:09:28","date_gmt":"2025-03-10T11:09:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/"},"modified":"2025-03-10T07:09:28","modified_gmt":"2025-03-10T11:09:28","slug":"regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/","title":{"rendered":"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">ROCKVILLE, Md.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 10, 2025<\/span><\/span> \/PRNewswire\/ &#8212; REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I\/II portion of the AFFINITY DUCHENNE<sup>\u00ae<\/sup> trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference, taking place in <span class=\"xn-location\">Dallas, TX<\/span>, <span class=\"xn-chron\">March 16-19, 2025<\/span>.<\/p>\n<p>\n        <b>Title: <\/b>RGX-202, an investigational gene therapy for the treatment of Duchenne Muscular Dystrophy: Interim clinical data (O75)<br \/><b>Session:<\/b> Clinical Trials<br \/><b>Date\/Time:<\/b><span><span class=\"xn-chron\">Wednesday, March 19, 2025<\/span>; <span class=\"xn-chron\">8:15 a.m. CT<\/span><br \/><\/span><b>Presenter: <\/b><span>Carolina <\/span><span class=\"xn-person\">Tesi Rocha<\/span><span>, M.D., Clinical Professor, Neurology, <span class=\"xn-person\">Stanford School<\/span> of Medicine, Stanford Children&#8217;s Health<\/span><\/p>\n<p>\n        <b>Title: <\/b>Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain (P143)<br \/><b>Session:<\/b> Pre-Clinical Research<br \/><b>Presenter: <\/b><span>Steven <\/span>Foltz<span>, <\/span>Ph.D<span>., Senior Scientist, Research &amp; Early Development at <\/span>REGENXBIO<\/p>\n<p>The presentations will be available in the Publications section of REGENXBIO&#8217;s website.<\/p>\n<p>\n        <b>ABOUT REGENXBIO Inc.<br \/><\/b>REGENXBIO\u00a0is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009,\u00a0REGENXBIO\u00a0has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines.\u00a0REGENXBIO\u00a0is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with\u00a0REGENXBIO&#8217;s\u00a0AAV Therapeutic platform, including Novartis&#8217; Zolgensma<sup>\u00ae<\/sup>\u00a0for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4379285-1&amp;h=586055048&amp;u=http%3A%2F%2Fwww.regenxbio.com%2F&amp;a=WWW.REGENXBIO.COM\" target=\"_blank\" rel=\"nofollow\">WWW.REGENXBIO.COM<\/a>.<\/p>\n<p>\n        <b>Contacts:<br \/><\/b><br \/>\n        <span>Dana <\/span>Cormack<br \/>Corporate Communications<br \/><a href=\"mailto:dcormack@regenxbio.com\" target=\"_blank\" rel=\"nofollow\">dcormack@regenxbio.com<\/a>\u00a0<\/p>\n<p>Investors:<br \/><span class=\"xn-person\">George E. MacDougall<\/span><br \/>Investor Relations<br \/><a href=\"mailto:IR@regenxbio.com\" target=\"_blank\" rel=\"nofollow\">IR@regenxbio.com<\/a>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder8818\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg\" title=\"(PRNewsfoto\/REGENXBIO Inc.)\" alt=\"(PRNewsfoto\/REGENXBIO Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH37017&amp;sd=2025-03-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical--scientific-conference-302396530.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical&#8211;scientific-conference-302396530.html<\/a><\/p>\n<p>SOURCE  REGENXBIO Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH37017&amp;Transmission_Id=202503100705PR_NEWS_USPR_____PH37017&amp;DateId=20250310\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire ROCKVILLE, Md. , March 10, 2025 \/PRNewswire\/ &#8212; REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I\/II portion of the AFFINITY DUCHENNE\u00ae trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference, taking place in Dallas, TX, March 16-19, 2025. Title: RGX-202, an investigational gene therapy for the treatment of Duchenne Muscular Dystrophy: Interim clinical data (O75)Session: Clinical TrialsDate\/Time:Wednesday, March 19, 2025; 8:15 a.m. CTPresenter: Carolina Tesi Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children&#8217;s Health Title: Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain (P143)Session: Pre-Clinical ResearchPresenter: Steven Foltz, Ph.D., Senior Scientist, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-823452","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire ROCKVILLE, Md. , March 10, 2025 \/PRNewswire\/ &#8212; REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I\/II portion of the AFFINITY DUCHENNE\u00ae trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference, taking place in Dallas, TX, March 16-19, 2025. Title: RGX-202, an investigational gene therapy for the treatment of Duchenne Muscular Dystrophy: Interim clinical data (O75)Session: Clinical TrialsDate\/Time:Wednesday, March 19, 2025; 8:15 a.m. CTPresenter: Carolina Tesi Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children&#8217;s Health Title: Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain (P143)Session: Pre-Clinical ResearchPresenter: Steven Foltz, Ph.D., Senior Scientist, &hellip; Continue reading &quot;REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T11:09:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference\",\"datePublished\":\"2025-03-10T11:09:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\",\"name\":\"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"datePublished\":\"2025-03-10T11:09:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/","og_locale":"en_US","og_type":"article","og_title":"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk","og_description":"PR Newswire ROCKVILLE, Md. , March 10, 2025 \/PRNewswire\/ &#8212; REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I\/II portion of the AFFINITY DUCHENNE\u00ae trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference, taking place in Dallas, TX, March 16-19, 2025. Title: RGX-202, an investigational gene therapy for the treatment of Duchenne Muscular Dystrophy: Interim clinical data (O75)Session: Clinical TrialsDate\/Time:Wednesday, March 19, 2025; 8:15 a.m. CTPresenter: Carolina Tesi Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children&#8217;s Health Title: Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain (P143)Session: Pre-Clinical ResearchPresenter: Steven Foltz, Ph.D., Senior Scientist, &hellip; Continue reading \"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-10T11:09:28+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference","datePublished":"2025-03-10T11:09:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/","name":"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","datePublished":"2025-03-10T11:09:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical-scientific-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=823452"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823452\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=823452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=823452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=823452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}